Egetis Therapeutics : ’ Corporate presentation

Corporate presentation

January 2022

A specialised late-stage orphan drug development company

Disclaimer

The information contained in this presentation is strictly confidential. Accordingly, the information included herein may not be referred to, quoted or otherwise disclosed by you, neither directly or indirectly nor wholly or partly. By reviewing this information, you are acknowledging the confidential nature of this information and are agreeing to abide by the terms of this disclaimer. This confidential information is being made available to each recipient solely for its information and is subject to amendment.

The company presentation, which should be understood to include these slides, their contents or any part of them, any oral presentation, any question or answer session and any written or oral materials discussed or distributed during a company presentation (the " Investor Presentation "), has been prepared by Egetis Therapeutics AB( publ ) (" or the Company "), to be used solely for a company presentation.

This Investor Presentation may not, without the prior written consent of the Company or it's Financial Advisors, be copied, passed on, reproduced or redistributed, directly or indirectly, in whole or in part,

or disclosed by any recipient, to any other person, and it may not be published anywhere, in whole or in part, for any purpose or under any circumstances. By attending a meeting where this Investor Presentation is presented or by accessing information contained in or obtained from the Investor Presentation, including by reading this Investor Presentation, you agree to be bound by the limitations and notifications contained herein.

This Investor Presentation does not constitute or form part of, and should not be construed as, any offer, invitation, solicitation or recommendation to purchase, sell or subscribe for any securities in any jurisdiction and the Investor Presentation does not constitute, and should not be considered as, a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 June 2017 (the Prospectus Regulation ") and do not constitute an offer to acquire securities in the Company. The Investor Presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure. The information should be independently evaluated and any person considering an interest in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to proceeding with any interest. Prospective investors should not treat the contents of the Investor Presentation as an advice relating to legal, taxation or investment matters. The Company has not decided whether to proceed with a transaction.

This Investor Presentation has not been approved or reviewed by any governmental authority or stock exchange in any jurisdiction. The shares in the Company have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " Securities Act "), or under any of the relevant securities laws of any state or other jurisdiction of the United States of America. Certain information contained herein has been obtained from published sources prepared by other parties that the Company has deemed to be relevant and trustworthy. No Investor Presentation or warranty, express or implied, is made by the Company or the Financial Advisors as to the accuracy, completeness or verification of any information contained in the Investor Presentation. The Company has

not made any independent review of information based on public statistics or information from an independent third party regarding the market information that has been provided by such third party, the industry or general Publications.

By their nature, forward looking statements involve known and unknown

risks, uncertainties, assumptions and other factors as they relate to events and depend on circumstances that will or may occur in the future, whether or not outside the control of the Company. No assurance is given that such forward looking statements will prove to be correct. Prospective investors should not place undue reliance on forward looking statements. They speak only as at the date of this Investor Presentation and neither the Company undertakes any obligation to update these forward looking statements. Past performance does

not guarantee or predict future performance. Moreover, the Company doesn't undertake any obligation to review, update or confirm expectations or estimates or to release any revisions to any forward looking statements to reflect events that occur or circumstances that arise in relation to the content of the Investor Presentation.

This Investor Presentation as well as any other information provided by or on behalf of the Company in connection herewith shall be governed by Swedish law. The courts of Sweden, with the District Court of Stockholm as the first instance, shall have exclusive jurisdiction to settle any conflict or dispute arising out of or in connection with this Investor Presentation or related matters.

Corporate presentation | Egetis Therapeutics | 2022-01-05

2

Agenda

1. A new specialised late-stage orphan drug development company

2. Emcitate®

• Clinical development programme
• Commercial opportunity

3. Aladote®

4.

5.

A.

• Clinical development programme
• Commercial opportunity

The Orphan drug segment and path to market Summary

Appendix

Corporate presentation | Egetis Therapeutics | 2022-01-05

3

1.

A specialised late-stage orphan drug development company

New specialised late-stage orphan drug development company

1	Dedicated orphan drug development company with two
late-stage orphan drug assets: Emcitate® and Aladote®
2	Highly attractive orphan drug segment with potential
>$1Bn annual sales opportunity

3

4

5

Clear path to market approval in EU and US

Plan to launch through niche inhouse commercial organization in the EU and US

Combined core expertise in late-stageorphan clinical development, registration and commercialisation with

experience from:

Corporate presentation | Egetis Therapeutics | 2022-01-05

5